Literature DB >> 25483014

Hepatopulmonary shunting in patients with primary and secondary liver tumors scheduled for radioembolization.

Maciej Janusz Powerski1, Christoph Erxleben2, Christian Scheurig-Münkler3, Dominik Geisel4, Uwe Heimann5, Bernd Hamm6, Bernhard Gebauer7.   

Abstract

PURPOSE: In patients undergoing transarterial radioembolization (RE) of malignant liver tumors, hepatopulmonary shunts (HPS) can lead to nontarget irradiation of the lungs. This study aims at analyzing the HPS fraction in relation to liver volume, tumor volume, tumor-to-liver volume ratio, tumor vascularity, type of tumor, and portal vein occlusion.
MATERIALS AND METHODS: In the presented retrospective study the percentage HPS fraction was calculated from SPECT/CT after infusion of Tc-99m macroaggregated albumin (Tc-99m MAA) into the proper hepatic artery of 233 patients evaluated for RE.
RESULTS: HPS fractions correlate very weakly with liver volume (r=0.303), tumor volume (r=0.345), and tumor-to-liver volume ratio (r=0.340). Tumors with strong contrast enhancement (HPSmedian(range)=11.7%(46.3%); n=73) have significantly larger shunt fractions than tumors with little enhancement (HPS=8.3%(16.4%); n=61; p<0.001). Colorectal cancer metastases (HPS=10.6%(28.6%); n=68) and hepatocellular cancers (HPS=11.7%(39.4%); n=63) have significantly larger HPS fractions than metastases from breast cancer (HPS=7.4%(16.7%); n=40; p=0.012 and p=0.001). Patients with compression (HPS=13.9%(43.7%); n=33) or tumor thrombosis (HPS=15.8% (31.2%); n=33) of a major portal vein branch have significantly higher degrees of shunting than patients with normal portal vein perfusion (HPS=8.1% (47.0%); n=167; both p<0.001). The shunt fraction is largest in patients with HCC and thrombosis or occlusion of a major portal vein branch (HPS=16.6% (31.0%); n=32).
CONCLUSION: The degree of hepatopulmonary shunting depends on the type of liver tumor, tumor vascularity, and portal vein perfusion. There is little to no correlation of HPS with liver volume, tumor volume, or tumor-to-liver volume ratio.
Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Hepatopulmonary shunt; Liver tumor; Radioembolization

Mesh:

Substances:

Year:  2014        PMID: 25483014     DOI: 10.1016/j.ejrad.2014.11.004

Source DB:  PubMed          Journal:  Eur J Radiol        ISSN: 0720-048X            Impact factor:   3.528


  3 in total

1.  Reduction of Hepatopulmonary and Intrahepatic Shunts after Treatment with Sorafenib in Hepatocellular Carcinoma Patients.

Authors:  Huseyin Tugsan Balli; Kairgeldy Aikimbaev; Isa Guney Burak; Umur Anil Pehlivan; Ferhat Can Piskin; Sinan Sozutok
Journal:  Cardiovasc Intervent Radiol       Date:  2022-09-29       Impact factor: 2.797

2.  Hepatopulmonary Shunting: A Prognostic Indicator of Survival in Patients with Metastatic Colorectal Adenocarcinoma Treated with 90Y Radioembolization.

Authors:  Kazim H Narsinh; Mark Van Buskirk; Andrew S Kennedy; Mohammed Suhail; Naif Alsaikhan; Carl K Hoh; Kenneth Thurston; Jeet Minocha; David S Ball; Steven J Cohen; Michael Cohn; Douglas M Coldwell; Alain Drooz; Eduardo Ehrenwald; Samir Kanani; Charles W Nutting; Fred M Moeslein; Michael A Savin; Sabine Schirm; Samuel G Putnam; Navesh K Sharma; Eric A Wang; Steven C Rose
Journal:  Radiology       Date:  2016-07-19       Impact factor: 11.105

Review 3.  Safety of selective internal radiation therapy (SIRT) with yttrium-90 microspheres combined with systemic anticancer agents: expert consensus.

Authors:  Andrew Kennedy; Daniel B Brown; Jonas Feilchenfeldt; John Marshall; Harpreet Wasan; Marwan Fakih; Peter Gibbs; Alexander Knuth; Bruno Sangro; Michael C Soulen; Gianfranco Pittari; Ricky A Sharma
Journal:  J Gastrointest Oncol       Date:  2017-12
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.